Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal

Palvella Therapeutics' COO Kathleen Goin sold 4,302 shares worth ~$508,000 on March 18, 2026, through a pre-planned Rule 10b5-1 trading plan adopted in August. The sale should not raise concerns as it was a structured liquidity event tied to option exercises. The stock has surged 340% over the past year, supported by positive Phase 3 results for its lead candidate QTORIN rapamycin (95% of participants showed improvement), a planned New Drug Application submission in H2 2026, and a recent $230 million equity offering.

03/25/2026, 6:25 PM • The Motley Fool

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Palvella Therapeutics (NASDAQ: PVLA) closed its upsized public offering on February 27, 2026, raising $230.0 million in gross proceeds by selling 1,840,000 shares at $125.00 per share, including the full exercise of underwriters' option for 240,000 additional shares. The company plans to use the net proceeds to support development of its QTORIN rapamycin and QTORIN pitavastatin programs for rare skin diseases and vascular malformations.

03/02/2026, 7:30 AM • Benzinga

Palvella Therapeutics Announces Pricing of Upsized Public Offering

Palvella Therapeutics priced an upsized public offering of 1.6 million shares at $125 per share, raising $200 million in gross proceeds before underwriting costs. The clinical-stage biopharmaceutical company plans to use the funds to support development of its QTORIN rapamycin and QTORIN pitavastatin programs for rare skin diseases and vascular malformations. The offering is expected to close on February 27, 2026.

02/25/2026, 7:57 PM • GlobeNewswire

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Palvella Therapeutics announced it will host a conference call on February 24, 2026, at 8:00am ET to discuss topline results from the Phase 3 SELVA clinical trial of QTORIN 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations. The company plans to release results at 6:30am ET prior to the call.

02/23/2026, 5:00 PM • GlobeNewswire

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

Palvella Therapeutics reported positive Phase 2 trial results for QTORIN™ rapamycin gel in treating cutaneous venous malformations, with 73% of participants showing improvement and no serious adverse events reported.

12/15/2025, 6:00 AM • GlobeNewswire

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

Palvella Therapeutics introduced a new product candidate, QTORIN™ pitavastatin, targeting disseminated superficial actinic porokeratosis (DSAP), a rare genetic skin disease with no current FDA-approved therapies. The company plans to initiate a Phase 2 clinical trial in the second half of 2026.

11/05/2025, 6:00 AM • GlobeNewswire